Cerebrovascular effects of galantamine treatment in patients with Alzheimer's disease.

Phase 4

• Conditions: dementia; Alzheimer's disease; 10007963; 10012272; 10003216

• Registration Number: NL-OMON29762
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

meeting DSM IV-R criteria for dementia
meeting NINCDS-ADRDA criteria for probable AD
clinical dementia rating scale (CDR) of 0.5 to 1.5

Exclusion Criteria

contra-indication for or unwilling to receive treatment with cholinesterase inhibitors
major cerebrovascular disease (stroke)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Cerebral perfusion:<br /><br>- changes in cerebral blood flow during treatment with ChEI*s versus placebo<br /><br>- changes in dynamic cerebral autoregulation during treatment with ChEI*s<br /><br>versus placebo.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Progression of cerebrovascular lesions and changes in neuropsychological<br /><br>functioning.<br /><br>Evaluation of early-dose responses in CBF to ChEI treatment.</p><br>